These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. De Marzo AM; DeWeese TL; Platz EA; Meeker AK; Nakayama M; Epstein JI; Isaacs WB; Nelson WG J Cell Biochem; 2004 Feb; 91(3):459-77. PubMed ID: 14755677 [TBL] [Abstract][Full Text] [Related]
8. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Davies MA; Koul D; Dhesi H; Berman R; McDonnell TJ; McConkey D; Yung WK; Steck PA Cancer Res; 1999 Jun; 59(11):2551-6. PubMed ID: 10363971 [TBL] [Abstract][Full Text] [Related]
9. Scientists hopeful as they uncover molecular clues to prostate cancer. Vanchieri C J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357 [No Abstract] [Full Text] [Related]
10. Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Boulikas T Anticancer Res; 1997; 17(3A):1471-505. PubMed ID: 9179186 [TBL] [Abstract][Full Text] [Related]
11. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Dong JT; Sipe TW; Hyytinen ER; Li CL; Heise C; McClintock DE; Grant CD; Chung LW; Frierson HF Oncogene; 1998 Oct; 17(15):1979-82. PubMed ID: 9788441 [TBL] [Abstract][Full Text] [Related]
12. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Wang SI; Parsons R; Ittmann M Clin Cancer Res; 1998 Mar; 4(3):811-5. PubMed ID: 9533551 [TBL] [Abstract][Full Text] [Related]
13. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Pesche S; Latil A; Muzeau F; Cussenot O; Fournier G; Longy M; Eng C; Lidereau R Oncogene; 1998 Jun; 16(22):2879-83. PubMed ID: 9671408 [TBL] [Abstract][Full Text] [Related]
14. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505 [TBL] [Abstract][Full Text] [Related]
15. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Feilotter HE; Nagai MA; Boag AH; Eng C; Mulligan LM Oncogene; 1998 Apr; 16(13):1743-8. PubMed ID: 9582022 [TBL] [Abstract][Full Text] [Related]
16. Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. Cooney KA; Tsou HC; Petty EM; Miesfeldt S; Ping XL; Gruener AC; Peacocke M Clin Cancer Res; 1999 Jun; 5(6):1387-91. PubMed ID: 10389923 [TBL] [Abstract][Full Text] [Related]
17. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells. Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065 [TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of prostate cancer. Elo JP; Visakorpi T Ann Med; 2001 Mar; 33(2):130-41. PubMed ID: 11327116 [TBL] [Abstract][Full Text] [Related]
19. [PTEN: a tumor suppressor with original properties]. Roux P Bull Cancer; 1999 Jun; 86(6):522-5. PubMed ID: 10417424 [TBL] [Abstract][Full Text] [Related]
20. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. McMenamin ME; Soung P; Perera S; Kaplan I; Loda M; Sellers WR Cancer Res; 1999 Sep; 59(17):4291-6. PubMed ID: 10485474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]